Home › Research › Biomarkers
Heterogeneity in plasma p-tau217 response and its association with cognitive trajectories under lecanemab treatment
Sung Hoon Kang, Yu Jeong Park, Seungyun Lee, Jimin Kang, Seongin Lee, Eun Seong Lee, Hye Na Jung, Inseon Ryoo et al.. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026-08
Topic: Plasma and spinal-fluid biomarkers
Plasma p-tau217 levels decreased significantly from 3 months, with the greatest decline between 3 and 6 months, followed by a plateau. Two distinct trajectory groups were identified. Patients in the greater reduction group showed more favorable cognitive trajectories, particularly slower progression in Clinical Dementia Rating-Sum of Boxes (CDR-SB) scores. Hypertension was associated with a diminished biomarker response. These findings support plasma p-tau217 as an early pharmacodynamic biomarker and highlight its potential role in guiding individualized treatment strategies in routine clinical practice.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Kang, S. H., Park, Y. J., Lee, S., Kang, J., Lee, S., Lee, E. S., et al. (2026). Heterogeneity in plasma p-tau217 response and its association with cognitive trajectories under lecanemab treatment. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.71705
Vancouver
Kang SH, Park YJ, Lee S, Kang J, Lee S, Lee ES, et al. Heterogeneity in plasma p-tau217 response and its association with cognitive trajectories under lecanemab treatment. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026. doi:10.1002/alz.71705. PMID: 42535277.
BibTeX
@article{kang2026-42535277,
author = {Kang, Sung Hoon and Park, Yu Jeong and Lee, Seungyun and Kang, Jimin and Lee, Seongin and Lee, Eun Seong and Jung, Hye Na and Ryoo, Inseon and others},
title = {{Heterogeneity in plasma p-tau217 response and its association with cognitive trajectories under lecanemab treatment}},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
year = {2026},
doi = {10.1002/alz.71705},
pmid = {42535277},
url = {https://doi.org/10.1002/alz.71705}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Plasma p-tau217 levels decreased significantly from 3 months, with the greatest decline between 3 and 6 months, followed by a plateau.
- Two distinct trajectory groups were identified.
- Patients in the greater reduction group showed more favorable cognitive trajectories, particularly slower progression in Clinical Dementia Rating-Sum of Boxes (CDR-SB) scores.
- Hypertension was associated with a diminished biomarker response.
- These findings support plasma p-tau217 as an early pharmacodynamic biomarker and highlight its potential role in guiding individualized treatment strategies in routine clinical practice.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designlongitudinal study
- Participants153
- Evidence strengthModerate
How this study scored 73/100
Published in a leading specialty journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 41 of the 56 points we could judge it on, which is 73 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 2 / 4 | 153 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42535277) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 41 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 41 of the 56 points we could judge it on is 73 out of 100. |
| Total | 73 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers
Also tagged “p-tau217”
692 studies in the library carry the topic tag “p-tau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 692 tagged studies.